Ricerca avanzata

Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2015 Agosto;150(4) > Giornale Italiano di Dermatologia e Venereologia 2015 Agosto;150(4):449-59



Rivista di Dermatologia e Malattie Sessualmente Trasmesse

Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

Periodicità: Bimestrale

ISSN 0392-0488

Online ISSN 1827-1820


Giornale Italiano di Dermatologia e Venereologia 2015 Agosto;150(4):449-59


Biosimilar infliximab: an expert view

Genazzani A. 1, Altomare G. 2, Balato N. 3, Cusano F. 4, De Pità O. 5, Loconsole F. 6, Micali G. 7, Piaserico S. 8, Girolomoni G. 9

1 Ospedale A. Avogadro, Novara, Italy;
2 IRCCS Ospedale Galeazzi, Milan, Italy;
3 Università Federico II, Naples, Italy;
4 Azienda Ospedaliera G. Rummo, Benevento, Italy;
5 IDI, Rome, Italy;
6 Policlinico Universitario, Bari, Italy;
7 Policlinico Vittorio Emanuele, Catania, Italy;
8 Azienda Ospedaliera di Padova, Padua, Italy;
9 University of Verona, Verona, Italy

CT-P13, a biosimilar of infliximab, was the first biosimilar monoclonal antibody to be approved in both the European Union and Korea. As a monoclonal antibody, CT-P13 is a large molecule with a high molecular weight, and as such it differs from other biosimilars currently in the market. The comparability exercise for CT-P13, therefore, requires special consideration, as it was the first demonstration of biosimilarity between a biosimilar monoclonal antibody and its originator. This paper summarizes current regulations on the approval of biosimilars, describes the evidence leading to the approval of CT-P13, and discusses the potential role of this molecule in the Italian scenario on the basis of the view of a group of experts.

lingua: Inglese


inizio pagina